Humira propels Abbott, stent view weighs

was largely responsible for the surprisingly strong sales -- a factor that has also bolstered first-quarter results for Eli Lilly (LLY.N Sales of Humira, the company's biggest product, rose 18 percent to $1.65 billion, a bit higher than most analysts...